Analysis of the curative effect of lamivudine and thymopolypeptides enteric-coated tablets in treating chronic hepatitis B in 48 cases

Objective:To observe the clinical curative effect of lamivudine and thymopolypeptides enteric-coated tablets in treating chronic hepatitis B.Methods:96 cases of chronic hepatitis B were divided into two groups,in which 48 cases were given lamivudine at a dose of 100mg orally once a day for consecutive 48 weeks,while thymopolypetides enteric-coated tablets were given at a dose of 6mg orally three times a day at the same time for consecutive 12 weeks;48 cases as a comparative group took lamivudine only.On the 12th,24th,and 48th week during treatment as well as 20 weeks after discontinuation of serving the medicine,inspection was carried out to check the serum markers of hepatitis B virus,HBV DNA quantification,and ALT,while observing adverse response.Results:The recovery rate of ALT in the treatment group within 48 weeks of treatment and 20 weeks after discontinuation of medicine was 92% and 87% respectively,which was higher than that in the comparative group,which was 78% and 50% respectively(all P0.05).The treatment group,on the 12th,24th and 48th week during treatment and 20 weeks after discontinuation of medicine,the negative rate of HBeAg was 30%,32%,43% and 35% respectively,which was higher than that(7%,10%,17% and 15%) in the comparative group(all P0.05);the treatment group,ony the 48th week during treatment and 20 weeks after discontinuation of medicine,the rate of HBV DNA was 88% and 82% respectively,which was higher than that(68% and 47%) in the comparative group(all P0.05).No adverse response was found in the two groups.Conclusion:Lamivudine combind with thymopolypeptides enteric-coated tablets is able to effectively increase the ALT recovery rate,reduce the level of blood serum HBVDNA and increase the negative rate of HBeAg,with very light bad response.